Medicine with the Active Substance Cerliponase Tender - 146594296

The CHILDREN'S FACULTY HOSPITAL WITH POLYCLINIC BANSKÁ BYSTRICA has issued a Tender notice for the procurement of a Medicine with the Active Substance Cerliponase Alfa 150 Mg, Infusion Solution in the Slovakia. This Tender notice was published on 05 Aug 2026 and is scheduled to close on 10 Sep 2026, with an estimated Tender value of EUR 2678664.6. Interested bidders can access detailed Tender information, eligibility criteria, and complete bidding documents by referencing TOT Ref No. 146594296, while the tender notice number is 543540-2026 and Registering on the platform.

Expired Tender

Procurement Summary

Country: Slovakia

Summary: Medicine with the Active Substance Cerliponase Alfa 150 Mg, Infusion Solution

Deadline: 10 Sep 2026

Posting Date: 05 Aug 2026

Other Information

Notice Type: Tender

TOT Ref.No.: 146594296

Document Ref. No.: 543540-2026

Competition: ICB

Financier: Self Financed

Purchaser Ownership: Public

Tender Value: EUR 2678664.6

CPV Classification

33610000 - Medicinal products for the alimentary tract and metabolism

Purchaser's Detail

Name: Login to see tender_details

Address: Login to see tender_details

Email: Login to see tender_detailsLogin to see details

Tender Details

Medicine with the active substance cerliponase alfa 150 mg, infusion solution The subject of the order is Medicine with the active substance cerliponase alfa 150 mg, infusion solution Pharmaceutical form: sol inf 5 ml/150 mg+5 ml diluted solution (drug.inj.glass) Administration: intracerebroventricular use The drug cerliponase alfa belongs to a group of drugs known as enzyme replacement therapies. It is used to treat patients with neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency. People with with CLN2 disease, they lack or have too little of an enzyme called TPP1, which causes a build-up of substances called lysosomal storage substances. In people with CLN2 disease, these substances accumulate in some parts of the body, especially in the brain. This medicine replaces the missing one an enzyme called TPPA, thereby minimizing the accumulation of lysosomal storage substances. This medicine works by slowing down the progression of the disease. The recommended dose is 300 mg of cerliponase alfa administered once every two weeks by intracerebroventricular infusion. Doc Title: Medicine with the active substance cerliponase alfa 150 mg, infusion solution Contract Type: supplies
Document Type: Contract Notice Reference Number: 63-2026 Contract Type: supplies Estimated Value: 2678664.6 - EUR Authority Type: body-pl-cga Doc Title: Medicine with the active substance cerliponase alfa 150 mg, infusion solution Dispatch Date: 2026-08-04 Publish Date: 2026-08-05 Submission Date: 2026-09-10

Documents

 Tender Notice


Corresponding Contract Award Notice

No Contract Award Notice found for this tender. Please try using the Contract Award Search Page.


Similar Tenders

Request Demo
GiZ Tenders India

Procurement Documents for Slovakia

Access a comprehensive library of standard procurement documents specific to Slovakia. Here, you'll find all the essential forms, guidelines, and templates required for tender applications and submissions in Slovakia

Explore Procurement Documents for Slovakia


Want To Bid in This Tender?

Get Local Agent Support in Slovakia and 60 More Countries.

View All The Services


View Tenders By


Publish Tenders


Have Any Dispute With The Purchaser?